Nottingham University Hospitals

Nottingham NG7 2UH

4 studies enrolling now · 14 studies all time

What they study most

ADPKD, ANCA-Associated Vasculitis, Acute Ischemic Stroke Patients Receiving Reperfusion Therapy, Anemia, Autosomal Dominant Polycystic Kidney, BK Virus Infection, Chronic Graft-versus-host-disease, Cystic Fibrosis, Graft-versus-host Disease (GVHD), Granulomatosis With Polyangiitis, Granulomatosis With Polyangiitis (Wegener's), Hemorrhagic Cystitis

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• Study of INCA036978 in Participants With Myeloproliferative Neoplasms — Recruiting now
• Staphylococcus Aureus Network Adaptive Platform Trial — Recruiting now
• A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Running, not enrolling
• Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years — Completed
• GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease — Completed
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON — Stopped early
• Optimal Post Tpa-Iv Monitoring in Ischemic Stroke — Completed
• A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate — Completed
• Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) — Completed
• Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) — Stopped early
• Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus — Stopped early